Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
US11319376B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 3, 2017 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | May 7, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to combination therapy methods of treating a subject having cancer, comprising administering to the subject a) an effective amount of a pharmaceutical composition comprising a phosphatidylinositol 3-kinase (PI3K) pathway inhibitor, or a pharmaceutically acceptable salt thereof, and b) an effective amount of a pharmaceutical composition comprising a glucagon receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.